RC18 240 mg ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
11	重症筋無力症	1
53	シェーグレン症候群	1

11. 重症筋無力症

---

臨床試験数 : 315 /  薬物数 : 232 - (DrugBank : 77) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04302103 (ClinicalTrials.gov)	July 23, 2020	6/3/2020	A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis	A Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Systemic Myasthenia Gravis	Systemic Myasthenia Gravis	Biological: RC18 160mg;Biological: RC18 240 mg	RemeGen Co., Ltd.	NULL	Active, not recruiting	18 Years	70 Years	All	29	Phase 2	China

53. シェーグレン症候群

---

臨床試験数 : 283 /  薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04078386 (ClinicalTrials.gov)	November 21, 2019	18/7/2019	A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome	A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg	RemeGen Co., Ltd.	NULL	Completed	18 Years	65 Years	All	42	Phase 2	China